Get the Stockscreener App
1.70
65.24%
-3.19
After Hours:
1.68
-0.02
-1.18%
Outlook Therapeutics Inc Stock (OTLK) Latest News
Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss - Scrip
Outlook Therapeutics stock craters as the wet AMD drug fails Phase III trial - Yahoo Finance
Outlook Therapeutics stock craters as wet AMD drug fails Phase III trial - Clinical Trials Arena
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday? - Yahoo Finance
Outlook Therapeutics reports NORSE EIGHT trial results; shares slump By Investing.com - Investing.com South Africa
Outlook Therapeutics reports NORSE EIGHT trial results; shares slump - Investing.com
Outlook plunges as lead asset fails in wet AMD study - MSN
Outlook Therapeutics Trial of Eye Disease Treatment Misses Key Endpoint - MarketWatch
Great Point Partners LLC Sells 408,482 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Outlook stock plunges after study setback (OTLK:NASDAQ) - Seeking Alpha
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial - Marketscreener.com
Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $48.20 - Defense World
Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK), - Yahoo Finance
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
OTLK (Outlook Therapeutics) EV-to-Revenue : (As of Nov. 23, 2024) - GuruFocus.com
Metrics That Matter About Iterum Therapeutics Plc (NASDAQ: ITRM) - Stocks Register
Thinking Of Investing In Outlook Therapeutics Inc (NASDAQ: OTLK) Stock? Here’s What You Need To Know - Stocks Register
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - PR Newswire
(OTLK) Trading Signals - Stock Traders Daily
Great Point Partners LLC Bolsters Position in Outlook Therapeuti - GuruFocus.com
Learn to Evaluate (OTLK) using the Charts - Stock Traders Daily
Velan Capital Investment Management LP Increases Stake in Outloo - GuruFocus.com
Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Aterian Investment Partners acquires Outlook Group to support growth - Packaging Gateway
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewswire
Outlook Therapeutics CEO to Present at Guggenheim Healthcare Conference After EU Win | OTLK Stock News - StockTitan
Breakeven On The Horizon For Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Simply Wall St
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
The United States Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook, 2030 - Grand View Research
Outlook Therapeutics' (OTLK) Buy Rating Reiterated at BTIG Research - MarketBeat
Outlook Therapeutics Participates in a Virtual Investor CEO Connect Segment - Marketscreener.com
How the (OTLK) price action is used to our Advantage - Stock Traders Daily
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment - GlobeNewswire
Wet Age-Related Macular Degeneration Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Severe Acute Respiratory Syndrome (SARS) Therapeutics Market 2023 Outlook By Product, Trends and Forecast To (2024-2034) – IndiaPolitics.com - IndiaPolitics.com
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ForexTV.com
ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important - EIN News
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Outlook Therapeutics Awaits Wet AMD Trial Results Of ONS-5010 - RTTNews
OTLK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionOTLK - AsiaOne
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(OTLK) On The My Stocks Page - Stock Traders Daily
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 12 Analysts - Benzinga
Outlook Therapeutics CFO buys $28.4k in company stock - Investing.com India
Insider Buying: CFO Lawrence Kenyon Acquires Shares of Outlook T - GuruFocus.com
Outlook Therapeutics CFO buys $28.4k in company stock By Investing.com - Investing.com Australia
Neumora Therapeutics' SWOT analysis: navacaprant's potential lifts stock outlook - Investing.com
Great Point Partners LLC Raises Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
(OTLK) Investment Analysis - Stock Traders Daily
Great Point Partners LLC Grows Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLC - Defense World
Checking in on Outlook Therapeutics Inc (OTLK) after recent insiders movement - Knox Daily
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):